Is Reddit a Buy on the Dip?
Reddit (NYSE:RDDT) share price has been on the proverbial ropes…
Buy
64
AZN Quote, Financials, Valuation and Earnings
Last price:
$77.59
Seasonality move
:
6.86%
Day range:
$76.74 - $77.69
52-week range:
$62.75 - $87.68
Dividend yield:
2%
P/E ratio:
34.41x
P/S ratio:
4.48x
P/B ratio:
5.91x
Volume:
4.8M
Avg. volume:
6.3M
1-year change:
15.75%
Market cap:
$240.6B
Revenue:
$54.1B
EPS (TTM):
$2.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$14B | $1.11 | 8.37% | 57.32% | $85.10 |
|
AMGN
Amgen
|
$8.9B | $5.34 | 8.14% | 257.4% | $315.95 |
|
GSK
GSK PLC
|
$10.1B | $1.05 | 2.57% | 57.14% | $43.42 |
|
LLY
Eli Lilly and
|
$14.2B | $5.47 | 45.75% | 89.16% | $1,006.63 |
|
MRK
Merck &
|
$16.1B | $2.18 | -1.15% | 13.5% | $112.29 |
|
NVO
Novo Nordisk AS
|
$12.1B | $0.97 | 23.24% | 6.35% | $112.90 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$77.60 | $85.10 | $240.6B | 34.41x | $1.05 | 2% | 4.48x |
|
AMGN
Amgen
|
$313.71 | $315.95 | $168.5B | 41.55x | $2.38 | 2.91% | 5.07x |
|
GSK
GSK PLC
|
$39.49 | $43.42 | $80.5B | 24.94x | $0.40 | 3.94% | 2.04x |
|
LLY
Eli Lilly and
|
$813.48 | $1,006.63 | $730.6B | 69.47x | $1.50 | 0.66% | 16.33x |
|
MRK
Merck &
|
$94.57 | $112.29 | $238.9B | 14.05x | $0.81 | 3.3% | 3.74x |
|
NVO
Novo Nordisk AS
|
$77.15 | $112.90 | $342.5B | 23.50x | $0.52 | 1.88% | 8.18x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
41.27% | -0.475 | -- | 0.74x |
|
AMGN
Amgen
|
91.09% | 0.434 | 43.85% | 0.84x |
|
GSK
GSK PLC
|
53.74% | 0.176 | 29.19% | 0.49x |
|
LLY
Eli Lilly and
|
70.33% | 0.371 | 5.05% | 0.59x |
|
MRK
Merck &
|
44.49% | 0.543 | 15.58% | 0.84x |
|
NVO
Novo Nordisk AS
|
40.09% | 0.871 | 3.51% | 0.52x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$12.2B | $2B | 9.88% | 17.77% | 14.07% | $2B |
|
AMGN
Amgen
|
$6B | $2.3B | 5.97% | 66.87% | 16.83% | $4.4B |
|
GSK
GSK PLC
|
$7.1B | $2.8B | 8.51% | 19.22% | 8.71% | $1.5B |
|
LLY
Eli Lilly and
|
$11.1B | $5.8B | 25.09% | 80.24% | 38.89% | $726.6M |
|
MRK
Merck &
|
$11.8B | $4.3B | 21.67% | 40.25% | 28.79% | $2.5B |
|
NVO
Novo Nordisk AS
|
$10.4B | $5.2B | 60.28% | 86.85% | 40.78% | -$786.4M |
AstraZeneca PLC vs. Competitors
-
Which has Higher Returns AZN or AMGN?
Amgen has a net margin of 10.07% compared to AstraZeneca PLC's net margin of 6.9%. AstraZeneca PLC's return on equity of 17.77% beat Amgen's return on equity of 66.87%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC81.7% $0.48 $69.5B AMGNAmgen65.75% $1.16 $66B -
What do Analysts Say About AZN or AMGN?
AstraZeneca PLC has a consensus price target of $85.10, signalling upside risk potential of 9.67%. On the other hand Amgen has an analysts' consensus of $315.95 which suggests that it could grow by 0.71%. Given that AstraZeneca PLC has higher upside potential than Amgen, analysts believe AstraZeneca PLC is more attractive than Amgen.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 2 0 AMGNAmgen9 14 2 -
Is AZN or AMGN More Risky?
AstraZeneca PLC has a beta of 0.412, which suggesting that the stock is 58.758% less volatile than S&P 500. In comparison Amgen has a beta of 0.527, suggesting its less volatile than the S&P 500 by 47.288%.
-
Which is a Better Dividend Stock AZN or AMGN?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2%. Amgen offers a yield of 2.91% to investors and pays a quarterly dividend of $2.38 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.
-
Which has Better Financial Ratios AZN or AMGN?
AstraZeneca PLC quarterly revenues are $14.9B, which are larger than Amgen quarterly revenues of $9.1B. AstraZeneca PLC's net income of $1.5B is higher than Amgen's net income of $627M. Notably, AstraZeneca PLC's price-to-earnings ratio is 34.41x while Amgen's PE ratio is 41.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.48x versus 5.07x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.48x 34.41x $14.9B $1.5B AMGNAmgen5.07x 41.55x $9.1B $627M
-
Which has Higher Returns AZN or GSK?
GSK PLC has a net margin of 10.07% compared to AstraZeneca PLC's net margin of 5.1%. AstraZeneca PLC's return on equity of 17.77% beat GSK PLC's return on equity of 19.22%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC81.7% $0.48 $69.5B GSKGSK PLC68.47% $0.26 $36.4B -
What do Analysts Say About AZN or GSK?
AstraZeneca PLC has a consensus price target of $85.10, signalling upside risk potential of 9.67%. On the other hand GSK PLC has an analysts' consensus of $43.42 which suggests that it could grow by 9.96%. Given that GSK PLC has higher upside potential than AstraZeneca PLC, analysts believe GSK PLC is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 2 0 GSKGSK PLC2 3 1 -
Is AZN or GSK More Risky?
AstraZeneca PLC has a beta of 0.412, which suggesting that the stock is 58.758% less volatile than S&P 500. In comparison GSK PLC has a beta of 0.601, suggesting its less volatile than the S&P 500 by 39.914%.
-
Which is a Better Dividend Stock AZN or GSK?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2%. GSK PLC offers a yield of 3.94% to investors and pays a quarterly dividend of $0.40 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. GSK PLC pays out 94.91% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or GSK?
AstraZeneca PLC quarterly revenues are $14.9B, which are larger than GSK PLC quarterly revenues of $10.4B. AstraZeneca PLC's net income of $1.5B is higher than GSK PLC's net income of $530.1M. Notably, AstraZeneca PLC's price-to-earnings ratio is 34.41x while GSK PLC's PE ratio is 24.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.48x versus 2.04x for GSK PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.48x 34.41x $14.9B $1.5B GSKGSK PLC2.04x 24.94x $10.4B $530.1M
-
Which has Higher Returns AZN or LLY?
Eli Lilly and has a net margin of 10.07% compared to AstraZeneca PLC's net margin of 32.59%. AstraZeneca PLC's return on equity of 17.77% beat Eli Lilly and's return on equity of 80.24%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC81.7% $0.48 $69.5B LLYEli Lilly and82.24% $4.88 $47.9B -
What do Analysts Say About AZN or LLY?
AstraZeneca PLC has a consensus price target of $85.10, signalling upside risk potential of 9.67%. On the other hand Eli Lilly and has an analysts' consensus of $1,006.63 which suggests that it could grow by 23.74%. Given that Eli Lilly and has higher upside potential than AstraZeneca PLC, analysts believe Eli Lilly and is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 2 0 LLYEli Lilly and16 4 0 -
Is AZN or LLY More Risky?
AstraZeneca PLC has a beta of 0.412, which suggesting that the stock is 58.758% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.
-
Which is a Better Dividend Stock AZN or LLY?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or LLY?
AstraZeneca PLC quarterly revenues are $14.9B, which are larger than Eli Lilly and quarterly revenues of $13.5B. AstraZeneca PLC's net income of $1.5B is lower than Eli Lilly and's net income of $4.4B. Notably, AstraZeneca PLC's price-to-earnings ratio is 34.41x while Eli Lilly and's PE ratio is 69.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.48x versus 16.33x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.48x 34.41x $14.9B $1.5B LLYEli Lilly and16.33x 69.47x $13.5B $4.4B
-
Which has Higher Returns AZN or MRK?
Merck & has a net margin of 10.07% compared to AstraZeneca PLC's net margin of 23.96%. AstraZeneca PLC's return on equity of 17.77% beat Merck &'s return on equity of 40.25%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC81.7% $0.48 $69.5B MRKMerck &75.5% $1.48 $83.5B -
What do Analysts Say About AZN or MRK?
AstraZeneca PLC has a consensus price target of $85.10, signalling upside risk potential of 9.67%. On the other hand Merck & has an analysts' consensus of $112.29 which suggests that it could grow by 18.73%. Given that Merck & has higher upside potential than AstraZeneca PLC, analysts believe Merck & is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 2 0 MRKMerck &11 10 0 -
Is AZN or MRK More Risky?
AstraZeneca PLC has a beta of 0.412, which suggesting that the stock is 58.758% less volatile than S&P 500. In comparison Merck & has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.24%.
-
Which is a Better Dividend Stock AZN or MRK?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2%. Merck & offers a yield of 3.3% to investors and pays a quarterly dividend of $0.81 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or MRK?
AstraZeneca PLC quarterly revenues are $14.9B, which are smaller than Merck & quarterly revenues of $15.6B. AstraZeneca PLC's net income of $1.5B is lower than Merck &'s net income of $3.7B. Notably, AstraZeneca PLC's price-to-earnings ratio is 34.41x while Merck &'s PE ratio is 14.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.48x versus 3.74x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.48x 34.41x $14.9B $1.5B MRKMerck &3.74x 14.05x $15.6B $3.7B
-
Which has Higher Returns AZN or NVO?
Novo Nordisk AS has a net margin of 10.07% compared to AstraZeneca PLC's net margin of 32.95%. AstraZeneca PLC's return on equity of 17.77% beat Novo Nordisk AS's return on equity of 86.85%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC81.7% $0.48 $69.5B NVONovo Nordisk AS84.8% $0.91 $33.4B -
What do Analysts Say About AZN or NVO?
AstraZeneca PLC has a consensus price target of $85.10, signalling upside risk potential of 9.67%. On the other hand Novo Nordisk AS has an analysts' consensus of $112.90 which suggests that it could grow by 48.19%. Given that Novo Nordisk AS has higher upside potential than AstraZeneca PLC, analysts believe Novo Nordisk AS is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 2 0 NVONovo Nordisk AS4 4 1 -
Is AZN or NVO More Risky?
AstraZeneca PLC has a beta of 0.412, which suggesting that the stock is 58.758% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.420, suggesting its less volatile than the S&P 500 by 58.038%.
-
Which is a Better Dividend Stock AZN or NVO?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2%. Novo Nordisk AS offers a yield of 1.88% to investors and pays a quarterly dividend of $0.52 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or NVO?
AstraZeneca PLC quarterly revenues are $14.9B, which are larger than Novo Nordisk AS quarterly revenues of $12.2B. AstraZeneca PLC's net income of $1.5B is lower than Novo Nordisk AS's net income of $4B. Notably, AstraZeneca PLC's price-to-earnings ratio is 34.41x while Novo Nordisk AS's PE ratio is 23.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.48x versus 8.18x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.48x 34.41x $14.9B $1.5B NVONovo Nordisk AS8.18x 23.50x $12.2B $4B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Qualcomm Stock: 5G Leader at a Bargain Price?
Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…
What Is Buffett Buying and Selling Now?
In Q4 of last year, Warren Buffett made a few…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
59
GRRR alert for Mar 15
Gorilla Technology Group [GRRR] is up 29.72% over the past day.
Sell
49
SMTC alert for Mar 15
Semtech [SMTC] is up 21.28% over the past day.
Buy
62
PLPC alert for Mar 15
Preformed Line Products [PLPC] is up 17.38% over the past day.
